Norditropin Efficacy in American Males with GHD from Pituitary Tumors: A Case Series
Reading Time: 2 minutes Introduction Growth hormone deficiency (GHD) is a condition that can significantly impact the quality of life, particularly when associated with pituitary tumors. In the United States, the prevalence of GHD among adults is estimated to be between 50 to 300 cases per million, with a notable impact on males due to the physiological and psychological implications of the disorder. Norditropin, a recombinant human growth hormone, has emerged as a pivotal treatment option for such patients. This article delves into a case series that evaluates the efficacy of Norditropin in American males diagnosed with GHD secondary to pituitary tumors, highlighting the...


